Quintiles appoints Oren Cohen Phase I development head
This article was originally published in Scrip
CRO Quintiles has appointed Dr Oren Cohen senior vice-president and global head of its Phase I clinical research division. Dr Cohen joined Quintiles in 2001 and was appointed chief medical and scientific officer in 2004. He is also consulting professor of medicine at Duke University Medical Center and a fellow of the Infectious Diseases Society of America.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.